1921
Volume 89, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Histoplasmosis is the first cause of acquired immunodeficiency syndrome (AIDS) and AIDS-related deaths in French Guiana. Cohort data were used to determine whether primary prophylaxis with 100 mg itraconazole for patients with CD4 counts < 150/mm was cost-effective with different scenarios. For a scenario where 12% of patients died, 60% were aware of their human immunodeficiency virus (HIV) infection and adherence was only 50%, primary prophylaxis would prevent 1 death and 9 cases of histoplasmosis for a cost of 36,792 Euros per averted death, 1,533 per life-year saved, 4,415 Euros per averted case, when only counting the costs of itraconazole prophylaxis. Taking into account the total costs of hospitalization showed that primary prophylaxis would allow a savings of 185,178 Euros per year. Even in a scenario of low adherence, primary prophylaxis would be cost-effective in French Guiana, and presumably in the rest of the Guianas and the Amazon.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.13-0082
2013-12-04
2017-11-19
Loading full text...

Full text loading...

/deliver/fulltext/14761645/89/6/1195.html?itemId=/content/journals/10.4269/ajtmh.13-0082&mimeType=html&fmt=ahah

References

  1. Nacher M, Adenis A, Adriouch L, Dufour J, Papot E, Hanf M, Vantilcke V, Calvez M, Aznar C, Carme B, Couppie P, , 2011. What is AIDS in the Amazon and the Guianas? Establishing the burden of disseminated histoplasmosis. Am J Trop Med Hyg 84: 239240.[Crossref]
  2. Hanf M, Adenis A, Couppie P, Carme B, Nacher M, , 2010. HIV-associated histoplasmosis in French Guiana: recent infection or reactivation? AIDS 24: 17771778.[Crossref]
  3. Wheat LJ, Freifeld AG, Kleiman MB, Baddley JW, McKinsey DS, Loyd JE, Kauffman CA, , 2007. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 45: 807825.[Crossref]
  4. INSEE, 2012. “Espérance de vie - Mortalité.”
  5. May M, Gompels M, Delpech V, Porter K, Post F, Johnson M, Dunn D, Palfreeman A, Gilson R, Gazzard B, Hill T, Walsh J, Fisher M, Orkin C, Ainsworth J, Bansi L, Phillips A, Leen C, Nelson M, Anderson J, Sabin C, , 2011. Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ 343: d6016.[Crossref]
  6. McKinsey DS, , 1998. Histoplasmosis in AIDS: advances in management. AIDS Patient Care STDS 12: 775781.[Crossref]
  7. World-Bank Bank W, , 1993. World Development Report. , ed. Washington DC. Available at: http://wdronline.worldbank.org/worldbank/a/c.html/world_development_report_1993/abstract/WB.0-1952-0890-0.abstract1.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.13-0082
Loading
/content/journals/10.4269/ajtmh.13-0082
Loading

Data & Media loading...

  • Received : 12 Feb 2013
  • Accepted : 05 Jun 2013

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error